GlassScriptPhysician profile
Karl Rhea
NPI 1831201292
$4,627.58
in general payments reported to CMS, 2019-2025
20 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $667 · 2021: $1,041 · 2022: $559 · 2023: $367 · 2024: $321 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,124.84 | 2019-2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $836.43 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.45 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $427.43 | 2020-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $425.91 | 2019-2025 | Breztri, Airsupra |
| Esperion Therapeutics, INC. | $356.03 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $200.14 | 2019-2020 | |
| Amarin Pharma, INC. | $139.37 | 2020-2021 | |
| Glaxosmithkline, LLC. | $127.57 | 2019-2020 | |
| Pfizer INC. | $126.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $67.83 | 2022-2024 | Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $32.76 | 2021-2025 | |
| Medtronic, INC. | $27.96 | 2024 | Intellis Adaptivestim |
| Abbott Laboratories | $22.79 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $22.70 | 2022 | |
| Abiomed | $21.14 | 2025 | |
| Lundbeck LLC | $20.02 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $15.38 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.86 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Rhea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.